SummaryLevodopa (LD) has been the first choice in the management of Parkinson's disease (PD), since its introduction in the drug market; however, its prolonged use is related to the occurrence of motor complications, affecting the functionality and quality of life. Parkinson's disease is one of the most frequent among the neurodegenerative diseases in the world, and it is expected that the number of people who suffer it, will increase due to global population aging. The PD represents, nowadays and for the future, a high economic burden from all perspectives, including patients, payers, and society. So it is necessary to know about the use of LD in its treatment and to realize the quality of pharmacoeconomic studies in the past five years, to identify reliable sources of information related to the costs and benefits of this medication to contribute in making decisions. The aim of this paper is to assess the methodological quality of pharmacoeconomic studies related to the use of LD in PD, specifically those that are identified as cost-utility studies, applying the QHES instrument. A total of 19 articles were found, of which 5 met the inclusion criteria and were subjected to examination. The average overall score obtained after the evaluation was 77.2 out of 100, making evident a good quality of studies according to the method used.Keywords: Levodopa, Parkinson's disease, cost-utility, methodological quality, QHES (Quality of Health Economic Studies). La Levodopa (LD) ha sido desde su introducción en el mercado la primera elección en el manejo de la enfermedad de Parkinson (EP); sin embargo, su uso prolongado está relacionado con la aparición de complicaciones motoras, afectándose la funcionalidad y calidad de vida. La EP es una de las enfermedades neurodegenerativas que se presenta con mayor frecuencia en el mundo y se espera que el número de personas que la padecen aumente, debido al envejecimiento poblacional a nivel mundial. La EP representa, actualmente y a futuro, una alta carga económica desde todas las perspectivas, incluyendo: pacientes, pagadores y la sociedad; por lo cual es necesario conocer el uso de la LD en el tratamiento de la misma y lograr determinar la calidad de los estudios farmacoeconómicos realizados en los últimos cinco años, para identificar fuentes fiables de información relacionadas con los costos y los beneficios de este medicamento que aporten en la toma de decisiones. El objetivo de este artículo es evaluar la calidad metodológica de los estudios farmacoeconómicos relacionados con el uso de la LD en la EP, específicamente aquellos que se cataloguen como estudios de costo-utilidad, aplicando el instrumento QHES. Se encontraron en total 19 artículos, de los cuales cinco cumplieron los criterios de inclusión y fueron sometidos al respectivo análisis. El puntaje global promedio obtenido posterior a la evaluación fue de 77,2 sobre 100, haciendo evidente una buena calidad de los estudios de acuerdo con el método utilizado.Palabras clave: Levodopa, enfermedad de Parkinson, costo-utilidad, ca...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.